# US 2021/0060000 A1 · Novel nitrogen-containing heteroaryl compounds and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060000 A1
- Document ID: US20210060000A1
- Status: Published application
- Kind: A1
- Application number: 16/818,800
- Filed: 2020-03-13
- Published: 2021-03-04
- Earliest claimed: 2003-06-06
- Assignees: FibroGen, Inc.
- Applicants: FibroGen, Inc.
- Inventors: Michael P. Arend; Lee A. Flippin; Volkmar Guenzler-Pukall; Wen-Bin Ho; Eric D. Turtle; Xiaohui Du
- Web page: https://patentgrep.com/patent/US20210060000A1

## CPC

- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 38/1816: {Erythropoietin [EPO]}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 221/08: Aza-anthracenes
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 217/24: Oxygen atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-assocaited conditions by increasing endogenous erythropoietin in vitro and in vivo.

## Claims

### Claim at position 1

-20.(canceled)

### Claim 21

A method of treating anemia associated with chronic kidney disease in a patient undergoing dialysis, comprising administering to the patient a therapeutically effective amount of a compound of formula:
or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the patient has been diagnosed with hypertension.

### Claim 23 (depends on 21)

The method of claim 21, wherein the patient has been diagnosed with diabetes.

### Claim 24

A method of treating anemia associated with chronic kidney disease in a patient undergoing dialysis, comprising administering to the patient a therapeutically effective amount of a compound of formula:

### Claim 25 (depends on 21)

The method of claim 21, wherein the patient has been diagnosed with hypertension.

### Claim 26 (depends on 21)

The method of claim 21, wherein the patient has been diagnosed with diabetes.

### Claim 27

A method of treating anemia associated with chronic kidney disease in a patient who is not undergoing dialysis, comprising administering to the patient a therapeutically effective amount of a compound of formula:
or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 27)

The method of claim 27, wherein the patient has been diagnosed with hypertension.

### Claim 29 (depends on 27)

The method of claim 27, wherein the patient has been diagnosed with diabetes.

### Claim 30

A method of treating anemia associated with chronic kidney disease in a patient who is not undergoing dialysis, comprising administering to the patient a therapeutically effective amount of a compound of formula:

### Claim 31 (depends on 30)

The method of claim 30, wherein the patient has been diagnosed with hypertension.

### Claim 32 (depends on 30)

The method of claim 30, wherein the patient has been diagnosed with diabetes.
